SCHEMBL1373373

SCHEMBL1373373

OB(O)Oc1ccc(OCc2ccccc2)cc1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.66
CYP1A2 P05177 1/20 0.66
PTGS1 P23219 1/20 0.66
SLC6A2 P23975 1/20 0.66
CYP2C19 P33261 1/20 0.66
PTGS2 P35354 1/20 0.66
SLC6A3 Q01959 1/20 0.66
HIF1A Q16665 1/20 0.66
HDAC6 Q9UBN7 1/20 0.66
MAOB P27338 4/20 0.58
GAA P10253 1/20 0.58
MAPT P10636 1/20 0.58
MAOA P21397 1/20 0.58
RAB9A P51151 1/20 0.58
SMN1; SMN2 Q16637 1/20 0.58
L3MBTL1 Q9Y468 1/20 0.58
NR4A1 P22736 1/20 0.58
NR4A2 P43354 1/20 0.58
NR4A3 Q92570 1/20 0.58
BCHE P06276 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27781804 0.94 LMNA (0.58) LMNACYP1A2PTGS1SLC6A2CYP2C19
SCHEMBL9576709 0.87 LMNA (0.51) LMNACYP1A2PTGS1SLC6A2CYP2C19
SCHEMBL6662818 0.85 TSHR (0.58) LMNACYP1A2PTGS1SLC6A2CYP2C19
SCHEMBL16320997 0.84 LMNA (0.47) LMNACYP1A2PTGS1SLC6A2CYP2C19
SCHEMBL3900793 0.84 LMNA (0.64) LMNACYP1A2PTGS1SLC6A2CYP2C19
SCHEMBL1942638 0.84 MAOB (0.62) MAOBGAAMAPTMAOARAB9A
SCHEMBL8434886 0.84 CYP1A2 (0.59) LMNACYP1A2PTGS1SLC6A2CYP2C19
SCHEMBL339813 0.83 LMNA (0.82) LMNACYP1A2PTGS1SLC6A2CYP2C19
SCHEMBL27367676 0.83 LMNA (0.82) LMNACYP1A2PTGS1SLC6A2CYP2C19
SCHEMBL6059706 0.81 CYP1A2 (0.66) LMNACYP1A2PTGS1SLC6A2CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119707650-A Functionalized-surface chiral column aromatic hydrocarbon and preparation method and application thereof 宁夏大学 2025-03-28 CN claimed
CN-114478500-A Coumarin two-photon initiator and synthesis method and application thereof 浙江大学 2022-05-13 CN claimed
CN-119462382-B Polymerizable compound, liquid crystal composition comprising same and liquid crystal display device 石家庄诚志永华显示材料有限公司 2025-05-13 CN disclosed
CN-119462382-A Polymerizable compound, liquid crystal composition comprising same and liquid crystal display device 石家庄诚志永华显示材料有限公司 2025-02-18 CN disclosed
CN-117643584-A Preparation method of sulfachromone compound for candida albicans resistant medicine 广西民族大学 2024-03-05 CN disclosed
CN-112279768-B Polymerizable compounds and their use in liquid crystal displays 默克专利股份有限公司 2024-01-30 CN disclosed
CN-112898133-B Preparation method of trans-ketone intermediate 河北迈尔斯通电子材料有限公司 2022-11-15 CN disclosed
EP-1582250-B2 Absorbent with improved oxidation resistance and process for deacidifying fluid fluxes BASF SE (DE) 2022-03-09 EP disclosed
CN-105622580-B Benzimidazole as prolyl hydroxylase inhibitors 詹森药业有限公司 2019-06-21 CN disclosed
CN-105801550-B Novel chromene kinase modulator 理森制药股份公司 2019-06-14 CN disclosed
CN-106232585-B Triaizine compounds and its medicinal usage 日本烟草产业株式会社 2019-04-02 CN disclosed
CN-101528702-A Quinoline compounds and methods of use ARRAY BIOPHARMA INC (US) 2009-09-09 CN disclosed
US-20090186902-A1 Substituted Tetrahydroimidazopyridine Compounds and the Use Thereof in the Treatment of Pain and Other Conditions GRUENENTHAL GMBH (DE) 2009-07-23 US disclosed
CN-101448505-A PI3 kinase antagonists UNIV CALIFORNIA (US) 2009-06-03 CN disclosed
EP-2017263-A1 HETEROARYLAMIDE LOWER CARBOXYLIC ACID DERIVATIVE Daiichi Sankyo Company, Limited (JP) 2009-01-21 EP disclosed
CN-1913880-A Methods of treating ADAMTS-5-associated diseases WYETH CORP (US) 2007-02-14 CN disclosed
EP-1582250-A2 Absorbent with improved ocidation resistance and process for deacidifying fluid fluxes BASF AKTIENGESELLSCHAFT (DE) 2005-10-05 EP disclosed
US-20050202967-A1 an aliphatic amine, in particular an alkanolamine, and a non-hydroquinoid antioxidant for removal of CO2, H2S, SO2, CS2, HCN, COS, disulfides or mercaptans as impurities in reaction gases formed in the oxidation of organic materials to prevent the emission of above gases BASF AKTIENGESELLSCHAFT (DE) 2005-09-15 US disclosed
CN-1520298-A Pyrazolopyrimidines as therapeutic agents �����ʩ���عɷݹ�˾ 2004-08-11 CN disclosed
US-5196141-A Electrooptical display MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 1993-03-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090186902-A1 Substituted Tetrahydroimidazopyridine Compounds and the Use Thereof in the Treatment of Pain and Other Conditions HRH4, TRPV1, QDPR LMNA 1246/4885CYP1A2 197/4885PTGS1 85/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.